About Pike Therapeutics
Pike Therapeutics is a company based in Vancouver (Canada) founded in 2019 by Brad Miles. Pike Therapeutics has raised $4.85 million across 4 funding rounds. The company has 49 employees as of December 19, 2024. Pike Therapeutics offers products and services including Continuous Transdermal Delivery Technology and Weekly CBD Delivery System. Pike Therapeutics operates in a competitive market with competitors including Hyasynth Bio, IGC Pharma, Hempsana, Soul Biotech and Nura Lyfe Sciences, among others.
- Headquarter Vancouver, Canada
- Employees 49 as on 19 Dec, 2024
- Founders Brad Miles
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Pike Therapeutics Usa, Inc.
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$4.85 M (USD)
in 4 rounds
-
Latest Funding Round
$760 K (USD), Series A
Jun 30, 2026
-
Investors
Not available
-
Employee Count
49
as on Dec 19, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Pike Therapeutics
Pike Therapeutics offers a comprehensive portfolio of products and services, including Continuous Transdermal Delivery Technology and Weekly CBD Delivery System.
Enables sustained release of drugs like CBD for enhanced efficacy.
Provides continuous CBD administration to improve patient treatment outcomes.
People of Pike Therapeutics
Unlock access to complete
Unlock access to complete
Leadership Team
3 people
Member Team
1 people
Finance and Accounting
1 people
Advisory Team
1 people
Unlock access to complete
Funding Insights of Pike Therapeutics
Pike Therapeutics has successfully raised a total of $4.85M across 4 strategic funding rounds. The most recent funding activity was a Series A round of $760 thousand completed in June 2026. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investments & Acquisitions by Pike Therapeutics
Investment portfolio details for Pike Therapeutics
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Pike Therapeutics
Detailed financials for Pike Therapeutics
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Pike Therapeutics Comparisons
Peer comparison for Pike Therapeutics
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Pike Therapeutics
Pike Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Hyasynth Bio, IGC Pharma, Hempsana, Soul Biotech and Nura Lyfe Sciences, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Developer of cannabinoid products intended to treat neurological disorders
|
|
| Locked | Locked | Locked |
Pharmaceutical products targeting neurological disorders like Alzheimer's are developed.
|
|
| Locked | Locked | Locked |
CBD oil processing solutions from hemp plants are provided.
|
|
| Locked | Locked | Locked |
Psychedelics, mushrooms, and cannabinoids are developed for mental health treatments.
|
|
| Locked | Locked | Locked |
Delivers comprehensive psychedelic and cannabinoid therapeutics for neurological disorders.
|
Detailed competitors of Pike Therapeutics
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Pike Therapeutics
Complete news archive for Pike Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Pike Therapeutics
Pike Therapeutics was founded in 2019 and raised its 1st funding round 4 years after it was founded.
Pike Therapeutics is headquartered in Vancouver, Canada. It is registered at Vancouver, British Columbia, Canada.
Brad Miles is the current CEO of Pike Therapeutics. They have also founded this company.
Pike Therapeutics is a funded company, having raised a total of $4.85M across 4 funding rounds to date.
As of Dec 19, 2024, the latest employee count at Pike Therapeutics is 49.
Pike Therapeutics was founded in 2019 in Vancouver, Canada, as a developer in the biotechnology sector focused on psychedelic and cannabinoid-based drugs. Treatments are being created for conditions including chronic pain, inflammation, chemotherapy-induced nausea and vomiting, seizure disorders, and depression. These therapeutics are delivered transdermally to enable controlled and sustained drug release. Operations center on research and development of innovative delivery systems.
Pike Therapeutics's top competitors include IGC Pharma, Hyasynth Bio and Soul Biotech.
Pike Therapeutics offers Continuous Transdermal Delivery Technology and Weekly CBD Delivery System.